The US Food and Drug Administration (FDA) has raised serious concerns regarding the manufacturing standards of eye drops produced by Aspen Pharmacare at its sterile facility in Gqeberha, South Africa. In a warning letter, the FDA highlighted potential risks of microbial contamination due to inadequate controls. The FDA’s warning letter, published following a September audit, revealed that Aspen’s manufacturing processes…